Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.

Shorena Janelidze; Ulrika Nordström; Sebastian Kügler; Patrik Brundin

doi:10.1002/jgm.2779

Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.

Shorena Janelidze, Ulrika Nordström, Sebastian Kügler, Patrik Brundin

Research output: Contribution to journal › Article › peer-review

37 Downloads (Pure)

Abstract

Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.

Original language	English
Pages (from-to)	300-308
Journal	Journal of Gene Medicine
Volume	16
Issue number	9-10
DOIs	https://doi.org/10.1002/jgm.2779
Publication status	Published - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Clinical Memory Research Unit (013242610), Neuronal Survival (013212041)

Subject classification (UKÄ)

Neurosciences
Neurology

Access to Document

10.1002/jgm.2779

Wiley__Janelidze_et_al

http://www.ncbi.nlm.nih.gov/pubmed/25303717?dopt=Abstract

Cite this

@article{8754fe8398e74611aefae5829df9eb4f,

title = "Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.",

abstract = "Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.",

author = "Shorena Janelidze and Ulrika Nordstr{\"o}m and Sebastian K{\"u}gler and Patrik Brundin",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Memory Research Unit (013242610), Neuronal Survival (013212041)",

year = "2014",

doi = "10.1002/jgm.2779",

language = "English",

volume = "16",

pages = "300--308",

journal = "Journal of Gene Medicine",

issn = "1521-2254",

publisher = "John Wiley & Sons Inc.",

number = "9-10",

}

Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease. / Janelidze, Shorena; Nordström, Ulrika; Kügler, Sebastian et al.
In: Journal of Gene Medicine, Vol. 16, No. 9-10, 2014, p. 300-308.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.

AU - Janelidze, Shorena

AU - Nordström, Ulrika

AU - Kügler, Sebastian

AU - Brundin, Patrik

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Memory Research Unit (013242610), Neuronal Survival (013212041)

PY - 2014

Y1 - 2014

N2 - Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.

AB - Adeno-associated virus (AAV) vectors are used to deliver potentially therapeutic genes in clinical trials in Parkinson's disease (PD). Pre-existing immunity to AAV and a local neuroinflammatory response might negatively affect the efficacy of such AAV-mediated gene delivery.

U2 - 10.1002/jgm.2779

DO - 10.1002/jgm.2779

M3 - Article

C2 - 25303717

SN - 1521-2254

VL - 16

SP - 300

EP - 308

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

IS - 9-10

ER -

Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.

Abstract

Bibliographical note

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this